Lifeboat Foundation

Year 2022

Experiments such as this one cannot be funded with federal research dollars, though they break no U.S. laws. The work was conducted in China, not because it was illegal in the United States, the researchers said, but because the monkey embryos, which are difficult to procure and expensive, were available there. The experiment used a total of 150 embryos, which were obtained without harming the monkeys, “just like in the IVF procedure,” Tan said.

But such experiments, which combine human cells with those of animals, are nevertheless controversial. This work, and other work by Izpisua Belmonte, has moved so rapidly, bioethicists have had trouble keeping up.

Continue reading “International team creates first chimeric human-monkey embryos” »

Imagine using your cellphone to control the activity of your own cells to treat injuries and disease. It sounds like something from the imagination of an overly optimistic science fiction writer. But this may one day be a possibility through the emerging field of quantum biology.

Over the past few decades, scientists have made incredible progress in understanding and manipulating biological systems at increasingly small scales, from protein folding to genetic engineering. And yet, the extent to which quantum effects influence living systems remains barely understood.

Continue reading “Quantum physics proposes a new way to study biology—the results could revolutionize our understanding of how life works” »

A new publication in the May issue of Nature Aging by researchers from Integrated Biosciences, a biotechnology company combining synthetic biology and machine learning to target aging, demonstrates the power of artificial intelligence (AI) to discover novel senolytic compounds, a class of small molecules under intense study for their ability to suppress age-related processes such as fibrosis, inflammation and cancer.

The paper, “Discovering small-molecule senolytics with deep neural networks,” authored in collaboration with researchers from the Massachusetts Institute of Technology (MIT) and the Broad Institute of MIT and Harvard, describes the AI-guided screening of more than 800,000 compounds to reveal three drug candidates with comparable efficacy and superior medicinal chemistry properties than those of senolytics currently under investigation.

“This research result is a significant milestone for both longevity research and the application of artificial intelligence to drug discovery,” said Felix Wong, Ph.D., co-founder of Integrated Biosciences and first author of the publication. “These data demonstrate that we can explore chemical space in silico and emerge with multiple candidate anti-aging compounds that are more likely to succeed in the clinic, compared to even the most promising examples of their kind being studied today.”

DNA writing is an aspect of our industry that I’ve been closely watching for several years because it is a critical component of so many groundbreaking capabilities, from cell and gene therapies to DNA data storage. At the SynBioBeta Conference in 2018, the co-founder of a new startup that was barely more than an idea gave a lightning talk on enzymatic DNA synthesis — and I was so struck by the technology the company was aiming to develop that I listed them as one of four synthetic biology startups to watch in 2019. I watched them, and I wasn’t disappointed.

Ansa Biotechnologies, Inc. — the Emeryville, California-based DNA synthesis startup using enzymes instead of chemicals to write DNA — announced in March the successful de novo synthesis of a 1005-mer, the world’s longest synthetic oligonucleotide, encoding a key part of the AAV vector used for developing gene therapies. And that’s just the beginning. Co-founder Dan Lin-Arlow will be giving another lightning talk at this year’s SynBioBeta Conference in just a few weeks. I caught up with him in the lead up and was truly impressed by what Ansa Biotechnologies has accomplished in just 5 years.

Synthetic DNA is a key enabling technology for engineering biology. For nearly 40 years, synthetic DNA has been produced using phosphoramidite chemistry, which facilitates the sequential addition of new bases to a DNA chain in a simple cyclic reaction. While this process is incredibly efficient and has supported countless innovative breakthroughs (a visit to Twist Bioscience’s website will quickly educate you on exciting advances in drug discovery, infectious disease research, cancer therapeutics, and even agriculture enabled by synthetic DNA) it suffers from two main drawbacks: its reliance on harsh chemicals and its inability to produce long (read: complex) DNA fragments.

Incapable of replicating on their own, viruses must hijack other organisms, like bacteria, to continue their existence. Little wonder, then, that bacteria had to develop ways to fight back.

Among them is CRISPR, a kind of an immune system that keeps DNA records of previous infections and then uses a protein called Cas to attack viruses that show up again. When Cas reaches a targeted virus, it cleaves the viral DNA, protecting the bacteria from infection.

Researchers have harnessed that targeted, DNA-snipping ability as a gene editing tool for all kinds of organisms. CRISPR can now be found in a variety of fields doing a variety of jobs, from helping to fight sickle cell and high cholesterol in humans to gene editing animals and crops. It’s proven to be an amazingly versatile tool.

Researchers have engineered a robotic lionfish with synthetic arteries, similar to those found in a human’s circulatory system. The fish “blood” that runs through it serves as both the robot’s power source and controls its movement. The findings, published Wednesday in Nature, may propel the new wave of soft robots, in which inventors seek to improve lifelike automated machines for human connection.

Synthetic blood vessels in a new robotic fish could improve the technology needed to make lifelike robots run longer.

Human lifespan is intricately connected to the aging process of individual cells, and this means that scientists have spent decades trying to unravel the mysteries of cellular aging and exploring methods to slow down the ticking of the aging clock.

Longevity. Technology: In 2020, a group of researchers from the University of California San Diego identified two distinct mechanisms of cellular aging and genetically manipulated them to extend cell lifespan [1]. Now, their research has progressed to employ synthetic biology and gene circuits to delay the deterioration associated with cellular aging [2]. The team’s innovative approach could revolutionize scientific methods of aging prevention and contribute to reprogramming aging pathways in various human cell types.

Publishing in Science, the researchers describe how cells in yeast, plants, animals and humans all contain gene regulatory circuits responsible for several physiological functions, including aging. These gene circuits, akin to electric circuits controlling household devices, can operate in different ways, and the UC San Diego team discovered that cells don’t necessarily age the same way – it all depends on their genetic material and environment. The researchers found that cells can age either through DNA stability decline or mitochondrial decline.

Engineering organs to replace damaged hearts or kidneys in the human body may seem like something out of a sci-fi movie, but the building blocks for this technology are already in place. In the burgeoning field of tissue engineering, live cells grow in artificial scaffolds to form biological tissue. But to evaluate how successfully the cells develop into tissue, researchers need a reliable method to monitor the cells as they move and multiply.

Now, scientists at the National Institute of Standards and Technology (NIST), the U.S Food and Drug Administration (FDA) and the National Institutes of Health (NIH) have developed a noninvasive method to count the live cells in a three-dimensional (3D) scaffold. The real-time technique images millimeter-scale regions to assess the viability of the cells and how the cells are distributed within the scaffold—an important capability for researchers who manufacture complex biological tissues from simple materials such as living cells.

Their findings have been published in the Journal of Biomedical Materials Research Part A.

The WHO says covid is no longer an emergency, yet does not say where covid originated from. No one knows. What I know is that covid is a cute name for SARS/Coronavirus. Something made in a lab at UNC Chapel Hill with Ralph Baric and his collegue from Wuhan China which he shared his gain of function research with. However the Nature article published in 2015 has this disclaimer, yet there is no animal origin after more than 3 years. So what do we believe?

“30 March 2020 Editors’ note, March 2020: We are aware that this article is being used as the basis for unverified theories that the novel coronavirus causing COVID-19 was engineered. There is no evidence that this is true; scientists believe that an animal is the most likely source of the coronavirus.”

The results indicate that group 2b viruses encoding the SHC014 spike in a wild-type backbone can efficiently use multiple orthologs of the SARS receptor human angiotensin converting enzyme II (ACE2), replicate efficiently in primary human airway cells and achieve in vitro titers equivalent to epidemic strains of SARS-CoV. ACE2 🤔

Continue reading “A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence Medicine” »